TY - JOUR
T1 - Nanomedicine for the treatment of retinal and optic nerve diseases
AU - Zarbin, Marco Attilio
AU - Montemagno, Carlo
AU - Leary, James Francis
AU - Ritch, Robert
N1 - Funding Information:
Supported in part by Research to Prevent Blindness, Inc. (MAZ, RR), the Joseph DiSepio AMD Research Fund (MAZ), and the Jane Banks Research Fund of the New York Eye and Ear Infirmary, New York, NY (RR).
PY - 2013/2
Y1 - 2013/2
N2 - The earliest impact of nanomedicine in ophthalmology is likely to involve the areas of biopharmaceuticals, implantable materials (e.g. tissue regeneration scaffolds, bioresorbable materials), implantable devices (e.g. glaucoma drainage valves), and diagnostic tools (e.g. intraocular pressure (IOP) monitors). Nanotechnology will bring about the development of regenerative medicine (i.e. replacement and improvement of cells, tissues, and organs) and artificial vision. In this chapter, we review ophthalmic applications of nanotechnology in the following areas: drug and trophic factor therapy for glaucoma, retinal degenerative, and retinal vascular disease; gene therapy for retinal degenerative disease; regenerative medicine, including optogenetics and optic nerve regeneration; and diagnostics (minimally invasive IOP monitoring). Nanotechnology will play an important role in both early-stage and late-stage intervention in the management of blinding diseases.
AB - The earliest impact of nanomedicine in ophthalmology is likely to involve the areas of biopharmaceuticals, implantable materials (e.g. tissue regeneration scaffolds, bioresorbable materials), implantable devices (e.g. glaucoma drainage valves), and diagnostic tools (e.g. intraocular pressure (IOP) monitors). Nanotechnology will bring about the development of regenerative medicine (i.e. replacement and improvement of cells, tissues, and organs) and artificial vision. In this chapter, we review ophthalmic applications of nanotechnology in the following areas: drug and trophic factor therapy for glaucoma, retinal degenerative, and retinal vascular disease; gene therapy for retinal degenerative disease; regenerative medicine, including optogenetics and optic nerve regeneration; and diagnostics (minimally invasive IOP monitoring). Nanotechnology will play an important role in both early-stage and late-stage intervention in the management of blinding diseases.
UR - http://www.scopus.com/inward/record.url?scp=84871328875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871328875&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2012.10.003
DO - 10.1016/j.coph.2012.10.003
M3 - Review article
C2 - 23142104
AN - SCOPUS:84871328875
SN - 1471-4892
VL - 13
SP - 134
EP - 148
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
IS - 1
ER -